This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

This study has been terminated.
Information provided by:
AHS Cancer Control Alberta Identifier:
First received: August 15, 2005
Last updated: February 12, 2016
Last verified: September 2009

Although declining in incidence, gastric/gastroesophageal cancer is still a commonly diagnosed malignancy in Canada. Patients who have undergone surgical resection for early disease have a high rate of local recurrence and distant spread. More than 50% of patients present with either locally advanced or metastatic disease. Patients with advanced disease have an extremely poor prognosis, with average survival times ranging from 3 - 9 months. Development of new therapeutic approaches for locally advanced or metastatic gastric/gastroesophageal cancer, is clearly needed.

Despite its proven efficacy, ECF (epirubicin, cisplatin, and infusional 5-fluorouracil [5-FU]) has not been widely adopted in North America and is likely due to the technical difficulties and inconvenience associated with infusional chemotherapy. This study will substitute the oral chemotherapy drug capecitabine for infusional 5-FU in addition to substituting intravenous cisplatin with carboplatin (ECC - epirubicin, carboplatin and capecitabine). It is hoped that these substitutions will not only reduce the typical ECF related adverse effects but also allow for a more convenient administration of outpatient chemotherapy. It is also hoped that the genetic correlates of this study may also identify specific populations that preferentially benefit from ECC treatment.

Condition Intervention Phase
Gastric Cancer Esophageal Cancer Tumors Drug: Epirubicin Drug: Carboplatin Drug: Capecitabine Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Combined Phase I/II Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

Resource links provided by NLM:

Further study details as provided by AHS Cancer Control Alberta:

Primary Outcome Measures:
  • recommended phase II dose

Secondary Outcome Measures:
  • preliminary study of efficacy

Estimated Enrollment: 50
Study Start Date: October 2005
Study Completion Date: November 2007
  Show Detailed Description


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Advanced cancer
  • Gastric or esophageal cancer
  • Adequate organ function and bone marrow reserve
  • In general, patients must be 18 years or older
  • Life expectancy of > 12 weeks
  • World Health Organization (WHO) performance status 0-2
  • Left ventricular ejection fraction (LVEF) by multiple gated acquisition (MUGA) > 50%
  • Adequate organ function: hematological (ANC > 1.5 x 10^9/L; platelets > 100 x 10^9/L); hepatic (bilirubin < 1.5 x upper limit of normal [ULN]; AST/ALT < 3 x ULN); renal (calculated creatinine clearance > 60 ml/min).
  • Negative pregnancy test for females with child-bearing potential
  • Prior radiotherapy allowed but must be delivered to < 25% of bone marrow; must be completed > 4 weeks before study entry; and patients must have recovered from all side effects of the radiotherapy. Radiation must not be delivered to the sole response indicator lesion, unless there is documented evidence of disease progression in that site after completion of radiation.
  • Patients must be able to reliably tolerate and comply with oral/feeding tube administered medications (patients are considered eligible if the investigator deems that there is no malabsorption syndrome and no gastrointestinal [GI] obstruction that would impair the delivery of orally administered chemotherapy).
  • If patient has had prior anthracycline, cumulative dose must be < 300mg/m2 of doxorubicin or its equivalent.

Exclusion Criteria:

  • Abnormal organ function or active infection
  • Patients currently enrolled in another clinical trial involving active cancer treatment.
  • Treatment with doxorubicin > 300mg/m2 or its equivalent.
  • Serious medical conditions including myocardial infarction within 6 months prior to entry; unstable angina; active cardiomyopathy; unstable ventricular arrhythmia; congestive heart failure; uncontrolled hypertension; uncontrolled psychotic disorders; serious active infections; uncontrolled diabetes or any other medical condition that might be aggravated by study treatment.
  • Pre-existing neuropathy > grade 1
  • History of seizures or patients receiving anti-epileptic prophylaxis
  • Active and or progressive brain or leptomeningeal metastasis
  • Pregnant or lactating women
  • Patients with evidence or recent history of drug or alcohol abuse
  • Prior treatment with capecitabine or infusional 5-FU
  • Known hypersensitivity to carboplatin
  • 5-FU, anthracyclines or known dihydropyrimidine dehydrogenase (DPD) deficiency.
  • Patients that lack physical integrity of the gastrointestinal (GI) tract leading to intestinal obstruction.
  • Patients taking warfarin (Coumadin) or other coumarin derivatives.
  • Presence of any mentally incapacitating psychological condition.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00130936

Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Principal Investigator: Michael Sawyer, MD AHS Cancer Control Alberta
  More Information Identifier: NCT00130936     History of Changes
Other Study ID Numbers: GI-05-0046
Study First Received: August 15, 2005
Last Updated: February 12, 2016

Keywords provided by AHS Cancer Control Alberta:
phase I
solid tumors

Additional relevant MeSH terms:
Stomach Neoplasms
Esophageal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Stomach Diseases
Head and Neck Neoplasms
Esophageal Diseases
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors processed this record on August 16, 2017